Henry James International Management Inc. Reduces Position in Ascendis Pharma A/S (NASDAQ:ASND)

Henry James International Management Inc. lessened its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 12.8% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 21,351 shares of the biotechnology company’s stock after selling 3,146 shares during the quarter. Henry James International Management Inc.’s holdings in Ascendis Pharma A/S were worth $3,188,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in ASND. Signaturefd LLC grew its stake in Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after buying an additional 80 shares during the last quarter. Bessemer Group Inc. grew its stake in shares of Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 332 shares during the last quarter. Searle & CO. purchased a new position in shares of Ascendis Pharma A/S in the 2nd quarter valued at approximately $205,000. Rhumbline Advisers grew its stake in shares of Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 143 shares during the last quarter. Finally, Pursue Wealth Partners LLC purchased a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at approximately $217,000.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Citigroup lifted their target price on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. JPMorgan Chase & Co. lowered their target price on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a research note on Monday. Evercore ISI lifted their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, September 17th. Finally, Bank of America upped their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $195.92.

Ascendis Pharma A/S Trading Up 2.5 %

Shares of ASND opened at $128.37 on Monday. Ascendis Pharma A/S has a 12-month low of $86.54 and a 12-month high of $161.00. The stock has a market cap of $7.78 billion, a P/E ratio of -13.46 and a beta of 0.66. The company has a 50-day moving average of $133.42 and a two-hundred day moving average of $133.62.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. As a group, analysts forecast that Ascendis Pharma A/S will post -7.24 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.